WO2001034645A3 - Mutated il-13 molecules and their uses - Google Patents

Mutated il-13 molecules and their uses Download PDF

Info

Publication number
WO2001034645A3
WO2001034645A3 PCT/US2000/031044 US0031044W WO0134645A3 WO 2001034645 A3 WO2001034645 A3 WO 2001034645A3 US 0031044 W US0031044 W US 0031044W WO 0134645 A3 WO0134645 A3 WO 0134645A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecule
agonists
antagonists
residue
mutated
Prior art date
Application number
PCT/US2000/031044
Other languages
French (fr)
Other versions
WO2001034645A2 (en
Inventor
Raj K Puri
Yasuo Oshima
Bharat H Joshi
Original Assignee
Us Health
Raj K Puri
Yasuo Oshima
Bharat H Joshi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Raj K Puri, Yasuo Oshima, Bharat H Joshi filed Critical Us Health
Priority to AU15993/01A priority Critical patent/AU1599301A/en
Priority to CA002404763A priority patent/CA2404763A1/en
Priority to EP00978539A priority patent/EP1263785A2/en
Publication of WO2001034645A2 publication Critical patent/WO2001034645A2/en
Publication of WO2001034645A3 publication Critical patent/WO2001034645A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides antagonists and agonists of IL-13 activity. The antagonists comprise a mutation in which the glutamic acid at position 13 of the IL-13 molecule is changed to a neutral or a positively charged molecule. The antagonists can be used to reduce or end symptoms in conditions, such as asthma, allergic rhinitis, atopic dermatitis, and hepatic fibrosis in schistosomiasis, in which IL-13 is an initiator, mediator, or enhancer of the abnormal state. Additionally, the antagonists can be used to slow the growth of cells of cancers for which IL-13 is an autocrine growth factor. Such cancers include renal cell carcinoma, Kaposi's sarcoma, and Hodgkin's disease. The agonists comprise mutated IL-13s in which one or more of the residues at positions 112, 110, 109, 92, 69, or 66 are mutated to a neutrally charged residue, or one with a charge opposite to the charge of the residue found at that position in native IL-13, provided that the residue at position 13 of the molecule is not negatively charged. The agonists can be used as more potent agents to provoke an effect provided by IL-13. In particular, the agonists can be used as reagents in the maturation of monocytes into dendritic cells, or to pretreat bone marrow stem cell donors to reduce graft versus host disease in the recipient of the stem cells. Finally, the invention provides IL-13 receptor binding molecules with affinity for the IL-13 receptor at least about 3 times greater than that exhibited by wild-type IL-13. Also provided are methods and compositions for specifically delivering an effector molecule to a tumor cell by chimeric molecules comprising the effector molecule and an IL-13 receptor binding molecule, and pharmaceutical compositions comprising such chimeric molecules.
PCT/US2000/031044 1999-11-11 2000-11-10 Mutated il-13 molecules and their uses WO2001034645A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU15993/01A AU1599301A (en) 1999-11-11 2000-11-10 Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13
CA002404763A CA2404763A1 (en) 1999-11-11 2000-11-10 Mutated il-13 molecules and their uses
EP00978539A EP1263785A2 (en) 1999-11-11 2000-11-10 Mutated il-13 molecules and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16523699P 1999-11-11 1999-11-11
US60/165,236 1999-11-11

Publications (2)

Publication Number Publication Date
WO2001034645A2 WO2001034645A2 (en) 2001-05-17
WO2001034645A3 true WO2001034645A3 (en) 2002-03-07

Family

ID=22598038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031044 WO2001034645A2 (en) 1999-11-11 2000-11-10 Mutated il-13 molecules and their uses

Country Status (4)

Country Link
EP (1) EP1263785A2 (en)
AU (1) AU1599301A (en)
CA (1) CA2404763A1 (en)
WO (1) WO2001034645A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
AU2001288405B8 (en) * 1998-04-03 2007-06-14 The Penn State Research Foundation Amino acid substitution mutants of interleukin 13
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
WO2003016346A1 (en) * 2001-08-17 2003-02-27 Hitachi Chemical Co., Ltd. Ligands
CA2496948A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
JP2006503017A (en) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Immunogenic composition comprising IL-13 element and T cell epitope and therapeutic use thereof
ES2343965T3 (en) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services ANTI-CD22 ANTIBODIES AND MUTED IMMUNOCONGUJADOS.
EP3718564B1 (en) 2003-12-23 2023-10-11 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
US9072716B2 (en) 2005-04-15 2015-07-07 The United States of America, as represented by the Secretary Department of Health by Human Servies Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells
EP2311854B1 (en) 2005-07-29 2013-04-17 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
AU2010292069B2 (en) 2009-09-11 2015-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Improved Pseudomonas Exotoxin A with reduced immunogenicity
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
AR097651A1 (en) 2013-09-13 2016-04-06 Genentech Inc METHODS AND COMPOSITIONS THAT INCLUDE PURIFIED RECOMBINATING POLIPEPTIDES
BR112016004437A2 (en) 2013-09-13 2017-10-17 Genentech Inc immunotest and cell line selection methods, antibodies and kit
EP3049526B1 (en) * 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US11453900B2 (en) 2014-09-09 2022-09-27 Glycosyn LLC Alpha (1,3) fucosyltransferases for use in the production of fucosylated oligosaccharides
WO2016044707A1 (en) * 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031946A1 (en) * 1996-03-01 1997-09-04 Genetics Institute, Inc. Il-13 binding chain of il-13 receptor
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5919456A (en) * 1995-03-15 1999-07-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-13 receptor specific chimeric proteins
WO1999051643A1 (en) * 1998-04-03 1999-10-14 The Penn State Research Foundation Mutagenized il13-based chimeric molecules
WO2001025282A1 (en) * 1999-10-06 2001-04-12 The Penn State Research Foundation Il13 mutants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5919456A (en) * 1995-03-15 1999-07-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-13 receptor specific chimeric proteins
WO1997031946A1 (en) * 1996-03-01 1997-09-04 Genetics Institute, Inc. Il-13 binding chain of il-13 receptor
WO1999051643A1 (en) * 1998-04-03 1999-10-14 The Penn State Research Foundation Mutagenized il13-based chimeric molecules
WO2001025282A1 (en) * 1999-10-06 2001-04-12 The Penn State Research Foundation Il13 mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OSHIMA Y ET AL: "Conversion of interleukin-13 into a high affinity agonist by a single amino acid substitution.", BLOOD, vol. 94, no. 10 SUPPL. 1 PART 2, 15 November 1999 (1999-11-15), Forty-first Annual Meeting of the American Society of Hematology;New Orleans, Louisiana, USA; December 3-7, 1999, pages 171b, XP002170452, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
CA2404763A1 (en) 2001-05-17
AU1599301A (en) 2001-06-06
WO2001034645A2 (en) 2001-05-17
EP1263785A2 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
WO2001034645A3 (en) Mutated il-13 molecules and their uses
Pike et al. Hormone-dependent phosphorylation of the 1, 25-dihydroxyvitamin D3 receptor in mouse fibroblasts
Kirazov et al. Comparison of the Lowry and the Bradford protein assays as applied for protein estimation of membrane-containing fractions
WO2003037248A3 (en) Fibrin nanoparticles and uses thereof
JP2004525354A5 (en)
IL173362A0 (en) Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
JP2002535956A5 (en)
WO2001044177A3 (en) Somatostatin analogs, radiolabelled derivatives thereof and their use
Gadgil et al. Heparin elution of transcription factors from DNA-Sepharose columns
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
WO2005033130A3 (en) Mutated ig binding domains of protein l
WO2003052067A3 (en) Vector mediated organelle transfection
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
Chen et al. Heterologous expression and dough mixing studies of a novel cysteine-rich avenin-like protein
EP1315742A4 (en) Amino acid substitution mutants of interleukin 13
Il'ina et al. Amino acid sequence of RTX-A's isoform actinoporin from the sea anemone, Radianthus macrodactylus
JPS61257931A (en) Recovery of interleukin 2 polypeptide
Dasari et al. Optimization of the downstream process for high recovery of rhG-CSF from inclusion bodies expressed in Escherichia coli
CN114456275B (en) Synthesis method of multi-site single ubiquitin modified histone
Mechler et al. Preparation and properties of ribosomal subunits from mouse plasmocytoma tumors
Darby et al. Affinity purification of plasmid DNA directly from crude bacterial cell lysates
Gao et al. A cysteine in the repetitive domain of a high-molecular-weight glutenin subunit interferes with the mixing properties of wheat dough
CA3220312A1 (en) Redox sensitive cralbp mutant proteins
Yonath et al. New RNA recognition features revealed in ancient ribosomal proteins
US20200071687A1 (en) Subtilisin variants and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2404763

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000978539

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000978539

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)